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CHANGE OF SERUM ADRENAL ANDROGENS IN PROSTATIC 
CANCER PATIENTS AFTER BILATERAL ORCHIDECTOMY 
OR LHRH AGONIST TREA T恥1ENT
Hiroya OKA， Hiromitsu NEGORO， Yoshio SUGINO， 
Hiroshi 1 W AMほ A，Seiji MOROI and Mutushi KAWAKITA 
From the Department 01 Urology， Kobe City General Hospital 
Bilateral orchidectomy (ORX) or administration of luteinizing hormone releasing hormone 
agonist (LH悶-I)for prostatic cancer patients causes suppression of testicular androgens. However， 
the suppre白s岱叩s討ionof adrenal androge叩ns芯 by these treatment岱sおscontroversial 川w匂emeasured serum 
concentrations of testosterone (T)， 4引
(DHEA)， LH， follicle-stimulating hormone (FSH)， adrenocorticotropic hormone (ACTH) and cortisol 
before and after 3-12 months of the first hormonal treatment in 17 prostatic cancer patients who had 
received ORX (8 cases) or LHRH (9 cases). ORX and LHRH decreased serum T to the castration 
level significantly (ORX: p<O.OOl， LHRH: p<O.OOOl). ORX increased serum LH and FSH 
significantly (LH: p<O.OOl， FSH: p<O.OOl)， whereas LHRH decreased LH and FSH significantly 
(LH : p< 0.05， FSH : p<0.05). Neither treatment caused any significant change in ACTH or cortisol. 
ORX and LHRH decreased the serum A-dione significantly (ORX: p<O.Ol， LHRH: p<O.OOl). 
LHRH decreased the serum DHEA significantly (p<O.Ol)， whereas ORX did not decrease serum 
DHEA. These data suggest that ..medical" and '.surgical" castration， especially LHRH agonist， may 
decrease not only testicular androgens but also adrenal androgens. 
(Acta Urol. Jpn. 49: 521-525， 2003) 




















































Table 1. Serum levels of luteinizing hormone (LH)， follicle stimulating hormone (FSH)， testosterone 
(T)， adrenocorticotropic hormone (ACTH)， cortisol， 4-androstene-3， 17-dione (A-dione) and 
dehydroepiandrosterone (DHEA) in patients with prostate cancer before and after bilateral 
orchidectomy or LHRH agonist treatment 
Parameter 
Orchidectomy LHRH agonist 
Before treatment After treatment p Before treatment After treatment 
No. patients 8 9 
Age (years)*' 
Mean 79.5 76.8 
Range 69-91 69-85 
PSA (ng/ml)*2 
Mean 137.0 29.7 
Range 34.3-259.0 7.3-72.0 
LH (mean士S.D.:mlU/ml) 9.46i: 6.13 26.84土 7.58 0.0006 1O.80i: 10.15 0.32i: 0.12 
FSH (mlU/ml) 20.63士13.94 94.40i:22.77 0.0002 34.86i:26.79 8.44i: 4.01 
Testosterone (ng/ml) 4.6l:I: 1.83 0.15i: 0.05 0.001 4.67i: 1.16 0.14i: 0.07 
ACTH (pg/ml) 24.6l:I: 11.22 25.00土11.98 0.698 41.89 i: 33.43 28.22士15.31
Cortisol (μg/ml) 10.94i: 4.88 9.89i: 2.36 0.3587 9.83i: 4.72 8.76士 2.61
A-dione (ng/ml) 1.23i: 0.54 0.56i: 0.27 0.0045 1.26i: 0.52 0.48i: 0.21 
DHEA (ng/ml) 2.53土1.03 2.36i: 0.95 0.5359 3.04i: 1.27 2.66i: 1.41 
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Fig. 1. Serum levels of adrenocorticotropic hormone (ACTH) and cortisol 
before and aれerbilateral orchidectomy or LHRH agonist treatment. 
Data is presented as box-plots. Within the‘box'， al values of the 
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Fig. 2. Serum levels of 4-androstene-3， 17曲
dione (A・dione) and dehydroepian-
drosterone (DHEA) before and after 
bilaleral orchidectomy or LHRH ago-
nist treatment in each case are plotted. 
523 
および治療前後での LH，FSH， T， ACTH， corti-









































































Fig. 3. Serum levels of 4・androstene-3，17-dione (A-dione) and dehydroepian-
drosterone (DHEA) before and after orchidectomy or LH-RH agonist 
treatment. Data are presented as box-plots. Within the 'box'， al 


































した LHや FSHにより視床下部や下垂体に nega-
tive feedbackがかかる機構と何らか関与しているこ
とも推察される.














“CRH (corticotropin releasing hormone ;視床下部)
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